![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SH2B3 |
Gene summary for SH2B3 |
![]() |
Gene information | Species | Human | Gene symbol | SH2B3 | Gene ID | 10019 |
Gene name | SH2B adaptor protein 3 | |
Gene Alias | IDDM20 | |
Cytomap | 12q24.12 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B7Z7K6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10019 | SH2B3 | HCC1_Meng | Human | Liver | HCC | 2.36e-10 | 3.63e-02 | 0.0246 |
10019 | SH2B3 | HCC2 | Human | Liver | HCC | 2.53e-05 | 1.45e+00 | 0.5341 |
10019 | SH2B3 | Pt13.b | Human | Liver | HCC | 4.65e-07 | 2.04e-01 | 0.0251 |
10019 | SH2B3 | S027 | Human | Liver | HCC | 6.28e-07 | 5.44e-01 | 0.2446 |
10019 | SH2B3 | S028 | Human | Liver | HCC | 6.29e-12 | 5.15e-01 | 0.2503 |
10019 | SH2B3 | S029 | Human | Liver | HCC | 1.37e-13 | 6.61e-01 | 0.2581 |
10019 | SH2B3 | C21 | Human | Oral cavity | OSCC | 3.86e-06 | 1.94e-01 | 0.2678 |
10019 | SH2B3 | C30 | Human | Oral cavity | OSCC | 5.85e-11 | 5.17e-01 | 0.3055 |
10019 | SH2B3 | C38 | Human | Oral cavity | OSCC | 3.33e-03 | 4.37e-01 | 0.172 |
10019 | SH2B3 | C43 | Human | Oral cavity | OSCC | 1.34e-03 | 9.16e-02 | 0.1704 |
10019 | SH2B3 | EOLP-1 | Human | Oral cavity | EOLP | 1.25e-21 | 5.08e-01 | -0.0202 |
10019 | SH2B3 | SYSMH5 | Human | Oral cavity | OSCC | 1.51e-03 | 6.66e-02 | 0.0647 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003410912 | Liver | HCC | homotypic cell-cell adhesion | 55/7958 | 90/18723 | 2.81e-04 | 2.02e-03 | 55 |
GO:00301952 | Liver | HCC | negative regulation of blood coagulation | 33/7958 | 49/18723 | 3.86e-04 | 2.62e-03 | 33 |
GO:00075992 | Liver | HCC | hemostasis | 119/7958 | 222/18723 | 5.25e-04 | 3.41e-03 | 119 |
GO:19000472 | Liver | HCC | negative regulation of hemostasis | 33/7958 | 50/18723 | 6.74e-04 | 4.15e-03 | 33 |
GO:00434097 | Liver | HCC | negative regulation of MAPK cascade | 98/7958 | 180/18723 | 7.88e-04 | 4.74e-03 | 98 |
GO:00508172 | Liver | HCC | coagulation | 118/7958 | 222/18723 | 8.41e-04 | 5.03e-03 | 118 |
GO:005087822 | Liver | HCC | regulation of body fluid levels | 191/7958 | 379/18723 | 1.06e-03 | 6.11e-03 | 191 |
GO:00508192 | Liver | HCC | negative regulation of coagulation | 34/7958 | 53/18723 | 1.20e-03 | 6.68e-03 | 34 |
GO:007052712 | Liver | HCC | platelet aggregation | 40/7958 | 67/18723 | 3.35e-03 | 1.53e-02 | 40 |
GO:0071901 | Liver | HCC | negative regulation of protein serine/threonine kinase activity | 66/7958 | 120/18723 | 3.81e-03 | 1.68e-02 | 66 |
GO:00341102 | Liver | HCC | regulation of homotypic cell-cell adhesion | 22/7958 | 33/18723 | 4.38e-03 | 1.90e-02 | 22 |
GO:0034111 | Liver | HCC | negative regulation of homotypic cell-cell adhesion | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
GO:0043407 | Liver | HCC | negative regulation of MAP kinase activity | 34/7958 | 59/18723 | 1.36e-02 | 4.84e-02 | 34 |
GO:005134820 | Oral cavity | OSCC | negative regulation of transferase activity | 165/7305 | 268/18723 | 5.02e-14 | 2.74e-12 | 165 |
GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
GO:001056320 | Oral cavity | OSCC | negative regulation of phosphorus metabolic process | 246/7305 | 442/18723 | 6.12e-13 | 2.89e-11 | 246 |
GO:004593620 | Oral cavity | OSCC | negative regulation of phosphate metabolic process | 245/7305 | 441/18723 | 8.85e-13 | 4.09e-11 | 245 |
GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0472210 | Liver | HCC | Neurotrophin signaling pathway | 74/4020 | 119/8465 | 8.27e-04 | 3.26e-03 | 1.81e-03 | 74 |
hsa0472211 | Liver | HCC | Neurotrophin signaling pathway | 74/4020 | 119/8465 | 8.27e-04 | 3.26e-03 | 1.81e-03 | 74 |
hsa0472220 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa04722110 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa0472242 | Oral cavity | EOLP | Neurotrophin signaling pathway | 36/1218 | 119/8465 | 6.23e-06 | 3.87e-05 | 2.28e-05 | 36 |
hsa0472252 | Oral cavity | EOLP | Neurotrophin signaling pathway | 36/1218 | 119/8465 | 6.23e-06 | 3.87e-05 | 2.28e-05 | 36 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SH2B3 | SNV | Missense_Mutation | rs765614074 | c.1099G>A | p.Gly367Ser | p.G367S | Q9UQQ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SH2B3 | SNV | Missense_Mutation | rs559278672 | c.1192N>T | p.Arg398Cys | p.R398C | Q9UQQ2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SH2B3 | insertion | In_Frame_Ins | novel | c.780_781insTTTGGGCTGCCTCTGCTTTCCATCCCT | p.Val260_Arg261insPheGlyLeuProLeuLeuSerIlePro | p.V260_R261insFGLPLLSIP | Q9UQQ2 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
SH2B3 | SNV | Missense_Mutation | novel | c.56N>A | p.Pro19Gln | p.P19Q | Q9UQQ2 | protein_coding | deleterious(0.02) | benign(0.012) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SH2B3 | SNV | Missense_Mutation | rs374482426 | c.1393G>A | p.Val465Ile | p.V465I | Q9UQQ2 | protein_coding | tolerated(0.84) | benign(0.069) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SH2B3 | SNV | Missense_Mutation | c.1693C>A | p.Leu565Met | p.L565M | Q9UQQ2 | protein_coding | tolerated(0.17) | benign(0.155) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SH2B3 | SNV | Missense_Mutation | c.1507N>A | p.Ser503Thr | p.S503T | Q9UQQ2 | protein_coding | tolerated(0.47) | benign(0.005) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SH2B3 | SNV | Missense_Mutation | novel | c.1231G>A | p.Ala411Thr | p.A411T | Q9UQQ2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
SH2B3 | SNV | Missense_Mutation | c.674N>A | p.Arg225His | p.R225H | Q9UQQ2 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SH2B3 | SNV | Missense_Mutation | novel | c.1175N>A | p.Arg392Gln | p.R392Q | Q9UQQ2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10019 | SH2B3 | CLINICALLY ACTIONABLE, KINASE | candesartan | CANDESARTAN | 31327267 |
Page: 1 |